Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
PZ HTL SA

Acquisition Should Increase Routine Flow Cytometry Diagnostic Use in Research and Clinical Practice

By BiotechDaily International staff writers
Posted on 13 Aug 2013
Image: The MoFlo XDP flow cytometer has set the standard for cell sorting with functionality, speed, and improved sensitivity (Photo courtesy of Beckman Coulter Life Sciences).
Image: The MoFlo XDP flow cytometer has set the standard for cell sorting with functionality, speed, and improved sensitivity (Photo courtesy of Beckman Coulter Life Sciences).
A major American producer of instruments for biomedical testing has acquired access to flow cytometry reagents that were among the first of this genre to be both dry and temperature-stable with CE marking for routine in vitro diagnostic use in Europe.

Beckman Coulter Life Sciences (Indianapolis, IN, USA), which develops, manufactures, and markets products that simplify, automate, and innovate complex biomedical testing has acquired the flow cytometry business assets of the life science technology company ReaMetrix India Pvt. Ltd. (Bangalore, India).

Beckman Coulter Life Sciences' diagnostic systems are found in hospitals and other critical care settings around the world and generate data used by physicians to diagnose disease, make treatment decisions, and monitor patients. In the research sector, their instruments have been applied to complex biological problems including causes of disease and potential new therapies or drugs. Acquisition of ReaMetrix is expected to help Beckman Coulter to widen its tool and technology offerings that would simplify the sample preparation process and provide highly standardized reagent combinations to cytometry laboratories around the globe. The deal provides it with temperature-stable, single-dose, multi-color antibody cocktails targeting two key segments for flow cytometry - HIV monitoring and clinical research.

“This acquisition provides both immediate opportunity and long-term value,” said Mario Koksch, vice president and general manager of the cytometry business unit at Beckman Coulter Life Sciences. “The simplification of customer workflows will be dramatic. We will be able to offer customers an extended line of market leading technology while expanding our reach within two key segments for flow cytometry—HIV monitoring and clinical research.”

“Over the last decade, ReaMetrix has been developing technologies that improve access of diagnostic testing through innovation,” said Bala S. Manian, CEO of ReaMetrix India Pvt. Ltd. “The development of room temperature stable unitized flow reagents used in diagnostics and life sciences is an important component of that effort. For ReaMetrix, Beckman Coulter Life Sciences represents an opportunity to provide the global customer with an integrated and optimized solution involving both hardware and reagents. From our point of view, we now have the best chance of benefiting the intended target population as well as impacting the productivity of cytometrists around the world. ”

Related Links:
Beckman Coulter Life Sciences
ReaMetrix India Pvt. Ltd.


comments powered by Disqus

Channels

Genomics/Proteomics

view channel

New Program Encourages Wide Distribution of Genomic Data

A new data sharing program allows genomics researchers and practitioners to analyze, visualize, and share raw sequence data for individual patients or across populations straight from a local browser. The sequencing revolution is providing the raw data required to identify the genetic variants underlying rare diseases... Read more

Drug Discovery

view channel
Image: The nano-cocoon drug delivery system is biocompatible, specifically targets cancer cells, can carry a large drug load, and releases the drugs very quickly once inside the cancer cell. Ligands on the surface of the \"cocoon\" trick cancer cells into consuming it. Enzymes (the “worms\" in this image) inside the cocoon are unleashed once inside the cell, destroying the cocoon and releasing anticancer drugs into the cell (Photo courtesy of Dr. Zhen Gu, North Carolina State University).

Novel Anticancer Drug Delivery System Utilizes DNA-Based Nanocapsules

A novel DNA-based drug delivery system minimizes damage to normal tissues by utilizing the acidic microenvironment inside cancer cells to trigger the directed release of the anticancer drug doxorubicin (DOX).... Read more

Lab Technologies

view channel

Experimental Physicists Find Clues into How Radiotherapy Kills Cancer Cells

A new discovery in experimental physics has implications for a better determination of the process in which radiotherapy destroys cancer cells. Dr. Jason Greenwood from Queen’s University Belfast (Ireland) Center for Plasma Physics collaborated with scientists from Italy and Spain on the work on electrons, and published... Read more

Business

view channel

Interest in Commercial Applications for Proteomics Continues to Grow

Increasing interest in the field of proteomics has led to a series of agreements between private proteomic companies and academic institutions as well as deals between pharmaceutical companies and novel proteomics innovator biotech companies. Proteomics is the study of the structure and function of proteins.... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.